Reading between the stripes - launch of a new tool makes clinical trials accessible for every NETs patient

Summary

The first neuroendocrine tumor clinical trial finder for patients and physicians has been launched by Ancora.ai and NorCal CarciNET. The free online tool offers personalized, unbiased trial results and can be accessed at https://www.ancora.ai/neuroendocrine. It is also available at NorCal CarciNET',  INCA Alliance and NETRF's websites. 

1. Introduction:

Clinical trials are often the best (sometimes only) treatment option for neuroendocrine tumors (NETs) due to rapidly evolving research in the space and a dearth of good standard of care treatment options. However, identifying the right clinical trial is a tedious task even for specialist physicians, and a nearly impossible one for patients.

2. About the tool:

3. About NorCal CarciNET

4. About Ancora.ai AG: